Metastasizing ameloblastoma

Metastasizing ameloblastoma is a histologically benign conventional ameloblastoma that produces distant metastatic deposits which themselves retain bland, benign ameloblastomatous morphology.[1][2][3] It is distinguished from ameloblastic carcinoma, the cytologically malignant odontogenic carcinoma, precisely by the absence of malignant histology at both primary and secondary sites.[1][4] The diagnosis is therefore behavioral and retrospective: it can be established only once metastasis is documented, since neither the primary tumor's morphology nor its imaging predicts metastatic potential.[2][4]

The great majority arise in the posterior mandible, follow a protracted course marked by repeated local recurrences, and metastasize most often to the lungs years to decades after initial treatment.[2][5] Pathogenesis is not fully understood; most cases share the MAPK-pathway (predominantly BRAF V600E) alterations of conventional ameloblastoma, and metastasis is thought to occur chiefly by hematogenous and, less often, lymphatic routes.[6][7][8] Management centers on adequate primary resection and long-term surveillance, with resection of accessible metastatic deposits.[2][9]

Listed among the odontogenic carcinomas in 2005, the entity was moved in the 2017 WHO classification to the benign ameloblastomas as a distinct subtype (alongside unicystic and peripheral/extraosseous types), a placement retained in the 2022 (5th edition) classification.[3][10][11][38] It is defined as a histologically benign, typical ameloblastoma that metastasizes to distant sites, with both the primary and the metastasis showing benign ameloblastoma features — a construct deliberately parallel to metastasizing pleomorphic adenoma.[3]

• Preferred term: metastasizing ameloblastoma.
• Common alias / obsolete usage: "malignant ameloblastoma." WHO recommends against this term because it conflates a cytologically bland metastasizing tumor with ameloblastic carcinoma.[1][3]
• Key contrast: ameloblastic carcinoma shows cytologic atypia and can be diagnosed from the primary alone, independent of metastasis; metastasizing ameloblastoma cannot.[1][4][7]

Metastasis is a rare event, affecting roughly 2% of ameloblastomas, and validated cases are fewer still once strict diagnostic criteria are applied.[4][12][13] In the best-characterized pooled series, about 81% of primaries originated in the mandible, and tumors recurred on average roughly four times before metastasis appeared.[2]

• Site of primary: posterior mandible predominates, mirroring conventional ameloblastoma, of which about 80% are mandibular.[6][11]
• Metastatic sites: lung is the initial and dominant site (about 75%–88% of cases, frequently bilateral), followed by bone, liver, regional cervical lymph nodes, and rarely brain.[2][6][7]
• Latency: the interval from primary diagnosis to metastasis is long and variable — a median disease-free interval of roughly 9 years and an average approaching 18 years in different series.[2][5][12]
• Age/sex: reflects conventional ameloblastoma, with a broad age range and peak incidence in the fourth to fifth decades and no strong sex predilection.[6]

The primary tumor presents as a conventional ameloblastoma — a slow-growing, often painless expansile swelling of the posterior mandible, frequently asymptomatic until it is large.[6][11][14] Loosening of teeth, malocclusion, paresthesia, soft-tissue invasion, and facial deformity accompany advanced lesions.[6]

Tempo and red flags

The clinical signature is a long natural history punctuated by multiple local recurrences, often after conservative or incomplete surgery, culminating in late distant spread.[2][4] Features that should raise concern for eventual metastasis or malignant transformation include long tumor duration, repeated recurrences, and histologically confirmed extraosseous/soft-tissue extension, which independently predicts later metastasis or progression to ameloblastic carcinoma.[7][9]

Metastatic presentation

Pulmonary deposits are typically indolent and often asymptomatic, discovered on surveillance or incidental imaging rather than through respiratory symptoms, consistent with their benign histology.[2][4] Symptomatic presentations do occur when deposits reach vital structures — for example, orbital extension causing proptosis and visual loss, or regional nodal disease in the neck.[7][15] Hypercalcemia has been reported in widely disseminated disease.[2]

Imaging characterizes the jaw primary and its local aggressiveness; it does not distinguish a tumor destined to metastasize from ordinary conventional ameloblastoma.[2] The features below describe the typical mandibular primary, with maxillary differences noted.

Location and distribution

The lesion centers on the posterior mandible, molar–ramus region, with the body and angle most often involved; about 80% of ameloblastomas are mandibular and roughly 20% maxillary.[6][11] Maxillary lesions favor the posterior alveolus and antrum.[7][16]

Relationship to teeth and alveolar process

The tumor arises within tooth-bearing bone and may surround or envelop roots and the crowns of unerupted teeth, so it is sometimes associated with an impacted tooth, mimicking a dentigerous cyst when unilocular.[14][17] It expands the alveolus and extends toward the basal bone as it enlarges.

Periphery and shape

Borders are typically well defined and corticated, often scalloped between root apices.[18][19] Loss of demarcation and ill-defined margins correlate with advanced patient age and long lesion duration and signal more aggressive, infiltrative behavior.[18]

Internal architecture

The classic appearance is a multilocular radiolucency with coarse curved septa producing "soap-bubble" (larger loculi) or "honeycomb" (smaller loculi) patterns; multilocularity predominates in adults.[4][14][18] Smaller and younger-patient lesions are more often unilocular.[18] The lesion is fundamentally radiolucent; internal calcification is uncommon (reported in roughly 15% of a large cohort and associated with long-standing disease) and should not be expected.[18]

Effects on teeth and adjacent structures

• Root resorption, often smooth or "knife-edge," is characteristic and more frequent and extensive than in odontogenic keratocyst.[17][18][20]
• Tooth displacement is common.[18][21]
• Compared with odontogenic keratocyst, ameloblastoma shows greater lesion volume, more buccolingual expansion, more root resorption, and more tooth displacement; notably, even relatively small ameloblastomas may destroy surrounding bone.[19]

Growth pattern, cortical involvement, and extent

Slow concentric growth produces marked cortical expansion with thinning, and, at later stages, cortical perforation and soft-tissue extension.[17][18] Buccal/labial expansion predominates, and more than half of advanced cases show frank cortical destruction.[18][20] Microscopic tumor extends into marrow spaces beyond the radiographically apparent margin, which underlies recurrence after inadequate excision.[4][7]

Variants and maxillary considerations

Unicystic-appearing lesions present as a unilocular, often pericoronal radiolucency and may be indistinguishable from a dentigerous cyst on projection imaging.[14][17] Maxillary lesions behave more aggressively, with earlier perforation and extension into the antrum, nasal cavity, orbit, and skull base, and carry a worse prognosis.[7][11][16]

Because the defining event is distant spread, cross-sectional and whole-body imaging are integral to diagnosis and staging rather than optional adjuncts.

Chest imaging for pulmonary metastases

The lungs are the dominant metastatic site, typically as single or bilateral pulmonary nodules; thoracic imaging is the principal tool for detecting and following these deposits.[2] Closer follow-up with thoracic imaging is specifically recommended after resection of any ameloblastoma showing histologic extraosseous extension.[9]

Soft-tissue and marrow extent of the primary

Contrast-enhanced cross-sectional imaging characterizes the mixed cystic–solid internal content, mural solid nodules, and septal/rim enhancement that help separate ameloblastoma from simple cystic lesions, and better defines marrow and soft-tissue extent for surgical planning — information particularly important for maxillary tumors approaching the orbit, sinuses, and skull base.[7][17][22]

Whole-body staging

PET-CT is generally reserved for documented or suspected metastatic ameloblastoma, where it aids staging of distant disease.[7]

Radiographically the primary is a multilocular, expansile mandibular radiolucency; the metastasizing designation cannot be made from imaging and is confirmed only when a distant deposit is biopsied. The most consequential distinction is from ameloblastic carcinoma, because management and prognosis diverge sharply.

The highest-risk pitfall is mislabeling a cytologically malignant ameloblastic carcinoma as metastasizing ameloblastoma, or vice versa. The two cannot be separated clinically or radiographically, and misclassification distorts prognosis and surveillance.[1][4] Resolution requires histologic review of both the primary and the metastatic deposit: identical bland ameloblastoma morphology at both sites supports metastasizing ameloblastoma, whereas cytologic atypia, brisk or atypical mitoses, and necrosis indicate ameloblastic carcinoma; an elevated Ki-67 index is supportive.[1][2][23]

Both the primary and the metastatic deposits display the morphology of benign conventional ameloblastoma — epithelial islands or anastomosing strands with peripheral palisaded columnar cells showing reverse nuclear polarity and subnuclear vacuolization, surrounding loose stellate reticulum-like cells.[1][6] The follicular pattern is most common, followed by the plexiform pattern; acanthomatous, granular, and basaloid patterns occur less often.[6]

Radiologic–pathologic correlation and distinction from carcinoma

The defining diagnostic criterion is the absence of malignant cytology: no significant pleomorphism, hyperchromasia, abnormal mitoses, or necrosis at either site.[1][2] Ameloblastic carcinoma, by contrast, combines ameloblastomatous architecture with cytologic atypia and a high proliferative index, and can be diagnosed on the primary alone.[4][23] Useful adjuncts favoring carcinoma include an elevated Ki-67 labeling index and alpha-smooth muscle actin expression within the epithelial islands.[25][26] Immunohistochemically, ameloblastoma epithelium is positive for CK19, CK5, and p63, with CK14 in peripheral cells and calretinin/CK13 in stellate reticulum-like cells.[6]

Molecular findings

Ameloblastomas, including those that metastasize, are oncogene-driven and molecularly simple, with BRAF V600E the most frequent alteration (pooled prevalence roughly 70%–72%), enriched in mandibular tumors; SMO mutations predominate in maxillary tumors and are largely mutually exclusive with BRAF.[8][27][28][29] Additional MAPK-pathway mutations (FGFR2, KRAS, NRAS, HRAS) and non-MAPK mutations (SMO, CTNNB1, PIK3CA, SMARCB1) occur.[6][8] These alterations are shared with conventional ameloblastoma and do not by themselves identify metastatic potential, but they define actionable therapeutic targets.[27][30]

Primary tumor and prevention of metastasis

The cornerstone is adequate initial surgery. Radical resection with wide bony margins (commonly 1–1.5 cm, up to 1–2 cm) achieves recurrence rates near 8%–15%, whereas enucleation/curettage carries recurrence as high as 41%–55%.[13][23][30] Because metastasis characteristically follows repeated recurrences and multiple interventions, early definitive resection to avoid recurrence is the best available strategy to reduce metastatic risk.[2][4][5] All ameloblastomas should be regarded as having metastatic potential when surgical planning.[4]

Workup, referral, and surveillance

Diagnosis requires biopsy; maxillary and soft-tissue lesions warrant cross-sectional imaging for extent.[7] Lifelong follow-up is mandatory given latency measured in decades, with thoracic imaging surveillance particularly for tumors showing histologic extraosseous extension.[6][9] Management should occur in a head-and-neck/oral–maxillofacial multidisciplinary setting.

Treatment of metastatic disease

There is no standardized protocol. Surgical resection of accessible metastases — for example, pulmonary wedge resection — is preferred when feasible given their indolence.[2][6] For unresectable or disseminated disease, radiotherapy (including stereotactic approaches for oligometastatic deposits) and chemotherapy have been used with variable, generally limited benefit.[5][12][31] BRAF/MEK-targeted therapy (dabrafenib plus trametinib) produces frequent radiologic responses in BRAF V600E-mutated ameloblastoma and is a rational option for unresectable or metastatic disease after molecular testing; FGFR2- and SMO-directed agents are investigational alternatives.[27][30]

Prognosis

Behavior is typically indolent despite dissemination: in the validated Mayo series over half of patients were alive an average of about 10 years after metastasis, while those who died survived an average of roughly 3 years, and other series report median survival near 2 years after metastasis.[2][5] The absence of cytologic malignant transformation correlates with this relatively slow metastatic growth.[2]